Nath Bio-Genes (India) Ltd
Nath Bio-Genes (India) Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Future growth expectations for Nath Bio-Genes (India) Limited: - Targeting around 15% top-line growth over last year for H2 FY '26 (Devinder Khurana). Management expects around 15% revenue growth over the previous year for FY '26, with an aspirational target of reaching INR 500 crores revenue next year (FY '27), implying 15-20% growth potential.
From Nath Bio-Genes (India) Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
2 more points from Nath Bio-Genes (India) Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Nath Bio-Genes (India) Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- No new capital investment is being made currently in the Philippines as government permissions are pending; only time and energy are being invested to secure approvals (Page 17).
- The company is focusing on research and development (R&D) with increased investments to develop superior and innovative products; significant product registration efforts are ongoing under the Plant Varieties Protection Act (Pages 14 and 7).
- There is no plan to sell Aurangabad land; it will continue to be used for seed cultivation and retained as a valued asset (Page 14).
- A strategic focus remains on developing and launching new products across segments over the next 3-4 years to drive growth (Page 7).
2 more points from Nath Bio-Genes (India) Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Agricultural Food & other Products
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Nath Bio-Genes (India) Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- As of the conference call dated November 14, 2025, Nath Bio-Genes did not explicitly state the exact current order book or pending orders.
- However, it was mentioned that there is around INR 100 crores of advanced booking lying in their books, yet to be adjusted against receivables.
- The company expects that these advanced bookings, along with recoveries from the market, will reduce debtor levels.
2 more points from Nath Bio-Genes (India) Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Nath Bio-Genes (India) Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹52 Cr, net loss ₹0 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Nath Bio-Genes's management said in earlier quarters
Others in Agricultural Food & other Products this season
- TBI Corn (Q2 FY26)
Revenue from Operations for H1FY26: INR 1,367.0 Mn (45.5% YoY growth from H1FY25's INR 939.8 Mn). Key investor presentation takeaways from TBI Corn Ltd's Q2 FY2
- GRM Overseas (Q2 FY26)
362.4 Crores, up 14.9% YoY from Rs. Key investor presentation takeaways from GRM Overseas Ltd's Q2 FY26 investor presentation — and how it ranks against sector
- Uttam Sug.Mills (Q2 FY26)
561.27 Cr, up from Rs. Key investor presentation takeaways from Uttam Sugar Mills Ltd's Q2 FY26 investor presentation — and how it ranks against sector peers.
- Magadh Sugar (Q2 FY26)
Revenue: Rs 244 Cr (Q2FY26) vs Rs 265 Cr (Q2FY25) – decline of Rs 21 Cr . Key concall takeaways from Magadh Sugar & Energy Ltd's Q2 FY26 earnings call — and…
Arthneeti Pro · Annual
Nath Bio-Genes (India) Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Nath Bio-Genes (India) Ltd Q2 FY26 results?
Future growth expectations for Nath Bio-Genes (India) Limited: - Targeting around 15% top-line growth over last year for H2 FY '26 (Devinder Khurana). Management expects around 15% revenue growth over the previous year for FY '26, with an aspirational target of reaching INR 500 crores revenue next year (FY '27), implying 15-20% growth potential.
What is Nath Bio-Genes (India) Ltd share price analysis?
Nath Bio-Genes (India) Ltd currently shows a neutral. The stock trades at a P/E of 9.2 with a market cap of ₹313 Cr. Investors should review the full earnings analysis for detailed insights.
Is Nath Bio-Genes (India) Ltd planning capital expenditure?
No new capital investment is being made currently in the Philippines as government permissions are pending; only time and energy are being invested to secure approvals (Page 17).
Keep Nath Bio-Genes (India) Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.